MTOR and neoplasm: Whereas preliminary results from the SWITCH trial showed that there was no sequence effect using sunitinib and sorafenib, results from the RECORD-3 trial highlighted that everolimus treatment of sunitinib-resistant tumors was more efficacious than the reverse sequence; this later result suggests that sunitinib-dependent tumor adaptation is more specifically targetable by a mTOR inhibitor than are the everolimus-dependent tumor modifications by an anti-angiogenic agent [27].